Allergy Therapeutics - PDMR Dealings & Shareholding Update

Allergy Therapeutics

12/03/2026 07:00

RNS Number : 3113W

Allergy Therapeutics PLC

12 March 2026

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

 

PDMR Dealings & Shareholding Update

 

Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, announces that the Company has been notified by ZQ Group of the following.

 

A re-organisation took place within ZQ Group which involved the transfer of the majority of the Company's shares previously held by SkyGem Acquisition Limited to SkyGem International Holdings Limited, both entities being within ZQ Group (the "Transfer"). The Transfer was undertaken to optimise ZQ's internal holding structure of AGY shares. The Transfer did not result in any change to the ultimate beneficial ownership of Allergy Therapeutics plc.

 

Separately, SkyGem International Holdings Limited placed an aggregate of 209,600,000 shares to four investors at an average price of 10 pence per share. The shares placed are in the paper form and are restricted from trading in the AIM market within the twelve months following the placement. The placement was designed to optimise the shareholder base ahead of the Company's earlier announced plan of a potential dual listing in Hong Kong.

 

Following these transactions, ZQ Capital and related entities hold the following shares in Allergy Therapeutics plc:

 

Holding entity
Number of shares
SkyGem International Holdings Ltd
3,828,575,524
SkyGem Acquisition Ltd
2,150,665
ZQ Capital Ltd
315,343
Shen Zheqing
90,000
Total
3,831,131,532

The aggregate holdings above represent 60.5% of the Company's issued share capital. 

 

As a result of these transactions, Zheqing (Simon) Shen, a person discharging managerial responsibilities ("PDMR") by virtue of his position as a director of the Company, has notified the Company of the following dealings.

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker

Nigel Birks - Life Science Specialist Sales

+44 (0)20 7220 0500

 

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapies that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. For more information, please see www.allergytherapeutics.com.

 Notification and public disclosure of transactions by Director/persons discharging managerial responsibilities ("PDMR") and persons closely associated with them ("PCA") 

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
ZQ Capital Management Limited
2
Reason for the notification
a)
Position/status
Persons closely associated Mr. Zheqing Shen, Non-Executive Director of Allergy Therapeutics Plc.
b)
Initial notification/Amendment
Initial notification.
3
Details of the issuer, UK emission allowance market participant, auction platform or auctioneer
a)
Name
Allergy Therapeutics Plc
b)
LEI
213800PQ7AHK7KGVOE23
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary shares
b)
Nature of the transaction
(1) Transfers between SkyGem Acquisition Ltd to SkyGem International Holdings Ltd
(2) Transfers between SkyGem Acquisition Ltd to SkyGem UK Holding Ltd
(3) Transfers between SkyGem UK Holding Ltd to SkyGem International Holdings Ltd
(4) Sale of Ordinary Shares
c)
Price(s) and volume(s)
Price(s)
(1) £0.1080
(1) £0.0228
(2) £0.0228
(3) £0.0228
(4) $0.1087
(4) £0.1020
(4) $0.1086
(4) $0.1085
Volume(s)
(1) 150,925,926
(1) 1,993,473,455
(2) 1,893,776,143
(3) 1,893,776,143
(4) 1,840,000
(4) 189,334,000
(4) 3,684,000
(4) 14,742,000
d)
Aggregated information
· - Aggregated volume
· - Price
(1) 2,144,399,381 Ordinary Shares
(2) 1,893,776,143 Ordinary Shares
(3) 1,893,776,143 Ordinary Shares
(4) 209,600,000 Ordinary Shares
(1) £0.0288 per share
(2) £0.0228 per share
(3) £0.0228 per share
(4) £0.100 per share
e)
Date of the transaction
(1) 25/02/2026
(2) 25/02/2026
(3)25/02/2026
(4) 27/02/2026, 27/02/2026, 02/03/2026, 27/02/2026
f)
Place of the transaction
Outside a trading venue.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHDDGDXUGBDGLB